Each day of delayed antiviral receipt raised the risk of hospitalization or death 17.9%, but there was no association between ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...

Center at UCSF is pioneering the development of potent drug candidates aimed at preventing future coronavirus pandemics.

A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating ...

Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' ...

There's no need to track down complicated and obscure businesses. Some of the market's best income-producing stocks are ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future ...

Pfizer's Q1 2025 earnings call painted a picture of gritty efficiency, disciplined R&D, and a pipeline trying to hit warp ...

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and ...

Discover Pfizer's Q1 2025 earnings insights, including strategic R&D updates, financial guidance, and cost-saving initiatives.